Triomics raises $22M Series B for oncology-specific AI platform

Triomics raises $22M Series B for oncology-specific AI platform

Triomics, a startup building an AI platform tailored to oncology workflows, has raised $22 million in Series B funding led by Battery Ventures, with participation from existing backers Nexus Venture Partners, Lightspeed, and Y Combinator. Founded in 2021, the company initially focused on clinical trial matching but expanded into generating verifiable patient summaries and automating tumor registry submissions as LLM capabilities matured. The startup claims a fourfold increase in enterprise customers and a 10x jump in annualized recurring revenue over the past year.

Why it matters: Triomics occupies a narrow but defensible vertical slice of the AI-in-healthcare market — oncology-specific data pipelines that generalize poorly to other domains. By training models exclusively on oncology records and integrating directly into existing clinical tools at institutions like Memorial Sloan Kettering and Yale Cancer Center, the company is building a data moat in a segment where precision and compliance expectations are extreme. This mirrors a broader pattern in enterprise AI: generic agents handle summarization; vertical specialists capture sticky, higher-margin deployments where domain-specific training data creates a durable advantage.

The $22M raise is notable less for its size than for what it signals about capital-cycle dynamics in healthcare AI. While foundation-model labs chase billions, Triomics is scaling ARR 10x on a modest $37M total raised — a capital efficiency story that contrasts with the hyperscaler-subsidized distribution model dominating consumer AI. The company's expansion into mandated tasks like tumor registry reporting further locks in institutional stickiness, though competition from well-funded medical scribe platforms like Abridge remains a long-term risk.

#Triomics #OncologyAI #HealthTech #SeriesB #VerticalAI #ClinicalWorkflow